Cargando…

Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis

BACKGROUND: Rifampin is a key drug in antituberculosis chemotherapy because it rapidly kills the majority of bacilli in tuberculosis lesions, prevents relapse and thus enables 6-month short-course chemotherapy. Little is known about the pharmacokinetics of rifampin in children. The objective of this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schaaf, Hendrik Simon, Willemse, Marianne, Cilliers, Karien, Labadarios, Demetre, Maritz, Johannes Stephanus, Hussey, Gregory D, McIlleron, Helen, Smith, Peter, Donald, Peter Roderick
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2679060/ https://www.ncbi.nlm.nih.gov/pubmed/19386087 http://dx.doi.org/10.1186/1741-7015-7-19

Ejemplares similares

HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients
por: Rockwood, Neesha, et al.
Publicado: (2016)

Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir
por: Rabie, Helena, et al.
Publicado: (2020)

Influence of Single Nucleotide Polymorphisms on Rifampin Pharmacokinetics in Tuberculosis Patients
por: Thomas, Levin, et al.
Publicado: (2020)

Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis
por: Ngwalero, Precious, et al.
Publicado: (2021)

Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis
por: Sloan, Derek J., et al.
Publicado: (2017)

Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis
por: van der Laan, Louvina E., et al.
Publicado: (2021)

The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults
por: Mendell, Jeanne, et al.
Publicado: (2015)

The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects
por: Li, Ting, et al.
Publicado: (2022)

Pharmacodynamic Biomarkers for Quantifying the Mycobacterial Effect of High Doses of Rifampin in Patients with Rifampin-susceptible Pulmonary Tuberculosis
por: Said, Bibie N, et al.
Publicado: (2021)

Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus‐associated tuberculosis
por: Schutz, Charlotte, et al.
Publicado: (2020)

Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy
por: Naiker, Suhashni, et al.
Publicado: (2014)

Discordance in Mycobacterium tuberculosis Rifampin Susceptibility
por: Kalokhe, Ameeta S., et al.
Publicado: (2012)

Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children
por: Zhang, C, et al.
Publicado: (2010)

Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review
por: Jacobs, Tom G, et al.
Publicado: (2020)

Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study
por: Heysell, Scott K, et al.
Publicado: (2022)

How diverse is the diet of adult South Africans?
por: Labadarios, Demetre, et al.
Publicado: (2011)

Association of body weight and physical activity with blood pressure in a rural population in the Dikgale village of Limpopo Province in South Africa
por: Mkhonto, Seth S, et al.
Publicado: (2012)

Retraction: Association of body weight and physical activity with blood pressure in a rural population in the Dikgale village of Limpopo Province in South Africa
por: Mkhonto, Seth S, et al.
Publicado: (2013)

Mycobacterium tuberculosis and Rifampin Resistance, United Kingdom
por: Sam, I-Ching, et al.
Publicado: (2006)

Characterization of rifampin-resistant Staphylococcus aureus nasal carriage in patients receiving rifampin-containing regimens for tuberculosis
por: Huang, Yu-Tsung, et al.
Publicado: (2018)

Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis
por: Abdelgawad, Noha, et al.
Publicado: (2022)

Current research toward optimizing dosing of first-line antituberculosis treatment
por: McIlleron, Helen, et al.
Publicado: (2018)

Factors which influence the consumption of street foods and fast foods in South Africa-a national survey
por: Steyn, Nelia P, et al.
Publicado: (2011)

Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review
por: Lawn, Stephen D, et al.
Publicado: (2013)

Unusual association of COVID-19, pulmonary tuberculosis and human immunodeficiency virus, having progressed favorably under treatment with chloroquine and rifampin
por: Bouaré, Fah, et al.
Publicado: (2020)

Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas
por: Pienaar, Elsje, et al.
Publicado: (2018)

Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects
por: Mukai, Mayumi, et al.
Publicado: (2017)

Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects
por: Ford, S. L., et al.
Publicado: (2017)

Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection
por: Srivastava, Shashikant, et al.
Publicado: (2022)

Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir
por: Moultrie, Harry, et al.
Publicado: (2015)

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers
por: Pithavala, Y. K., et al.
Publicado: (2009)

Effects of rifampin coadministration on the pharmacokinetics of digoxin: a real-world data approach
por: Oh, JungJin, et al.
Publicado: (2023)

The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis
por: Somoskovi, Akos, et al.
Publicado: (2001)

Mycobacterium tuberculosis Beijing Genotype Resistance to Transient Rifampin Exposure
por: den Hertog, Alice L., et al.
Publicado: (2014)

Oxycodone Resistance Due to Rifampin Use in an Osteosarcoma Patient with Tuberculosis
por: Sakamoto, Akio, et al.
Publicado: (2017)

rpoB Mutations and Effects on Rifampin Resistance in Mycobacterium tuberculosis
por: Li, Ma-chao, et al.
Publicado: (2021)

Etymologia: Rifampin
por: Henry, Ronnie
Publicado: (2018)

Predictors of knowledge about tuberculosis: results from SANHANES I, a national, cross-sectional household survey in South Africa
por: Naidoo, Pamela, et al.
Publicado: (2016)

Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy
por: Svensson, Elin M., et al.
Publicado: (2017)

Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin‐resistant tuberculosis
por: Court, Richard, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o5kq4s7t09dsa5vbrojhjsp2r1